Approved indications
Doxorubicin IV is FDA-approved in adults and some pediatric patients for multiple malignancies, including: metastatic breast cancer; Hodgkin and non-Hodgkin lymphomas; acute lymphoblastic and acute myeloid leukemias; metastatic or unresectable soft tissue and bone sarcomas; small cell lung cancer; ovarian cancer; bladder cancer; gastric cancer; thyroid cancer; Wilms tumor; and neuroblastoma, often as part of combination regimens.

Off-label uses and evidence
Clinicians may use doxorubicin off-label in additional solid tumors or lymphoma/leukemia subtypes when data from clinical trials or treatment guidelines support anthracycline-based regimens; evidence is generally moderate to strong because many large oncology trials and guidelines (e.g., for lymphomas and sarcomas) are built around doxorubicin-containing combinations.

Efficacy expectations
Depending on the cancer type and stage, signs of response (tumor shrinkage, improved blood counts, symptom relief) are usually assessed after 1–3 treatment cycles (about 3–9 weeks) using imaging and labs. Many standard regimens with doxorubicin (such as those for lymphomas, breast cancer, or sarcomas) have well-established response and survival benefits and often form the backbone of first-line therapy. Compared with some newer targeted therapies or immunotherapies, doxorubicin has similar or higher initial tumor-killing power in certain cancers but more cumulative toxicity, especially to the heart, and is therefore dosed with strict lifetime limits and cardiac monitoring.

Typical dosing and administration
Doxorubicin is given only by intravenous infusion or slow injection by trained oncology staff. For many adult solid tumors and lymphomas, typical doses are about 60–75 mg/m² IV once every 21 days, or 40–60 mg/m² IV on day 1 of a 21‑day cycle in combination regimens; for some leukemias and pediatric regimens, 20–30 mg/m² IV may be given on several consecutive days per cycle. Total lifetime cumulative doses are usually limited to about 450–550 mg/m² (or lower in high-risk patients) to reduce heart damage risk. It is not taken by mouth and is not tied to meals, but infusion times and premedications (such as anti-nausea drugs) are scheduled by the oncology team.

Special dosing instructions
Doses may be reduced or delayed based on blood counts, liver function tests, prior anthracycline exposure, age, and cardiac status. Baseline and periodic heart tests (such as echocardiograms or MUGA scans) are often performed, especially as cumulative dose increases. Central venous access (port or PICC) is frequently used to reduce the risk of vein irritation and tissue injury.

Missed doses
If a dose or cycle is missed or delayed, the oncology team will decide when and how to resume based on blood counts, side effects, and overall treatment goals; patients should not attempt to adjust schedules on their own.

Overdose
Suspected overdose or accidental extra dosing is a medical emergency; management may include hospitalization, intensive monitoring, supportive care for severe bone marrow suppression and heart dysfunction, and, when appropriate, use of specific supportive agents such as growth factors, as directed by oncology and critical-care specialists.

Common side effects
Very common effects include nausea, vomiting, loss of appetite, diarrhea or mouth sores, temporary hair loss, darkening of nails or skin, and fatigue. Bone marrow suppression (low white cells, red cells, and platelets) typically occurs 7–14 days after a dose, increasing infection, anemia, and bruising risk; these effects are usually reversible between cycles. Urine may turn red for 1–2 days after infusion due to the drug’s color.

Serious or rare adverse effects
Important serious risks include heart damage (cardiomyopathy and heart failure), which can appear during treatment or months to years later, especially at higher cumulative doses or with prior heart disease or chest radiation. Severe neutropenia and infections, sepsis, and bleeding can occur and may require urgent medical care and hospitalization. Rare but serious reactions include secondary leukemias, severe infusion reactions, and severe local tissue injury if the drug leaks outside the vein (extravasation).

Warnings and precautions
Doxorubicin is not recommended in pregnancy unless the potential benefit justifies the risk; it can harm an unborn baby, and effective contraception is advised during treatment and for a period after the last dose for both sexes. Breastfeeding is generally not recommended during therapy and for some time after because the drug can pass into breast milk. Caution and dose adjustments may be needed in patients with liver impairment, prior or current heart disease, prior anthracycline exposure, or prior chest radiation. Elderly patients and very young children may be at higher risk for heart problems and may require closer monitoring.

Comparative safety
Compared with many other chemotherapy drugs, doxorubicin has a well-known risk of dose-related and sometimes delayed cardiotoxicity, so total lifetime dose is limited and heart function must be checked over time. Its non-cardiac side effects (nausea, hair loss, low blood counts) are broadly similar to those of other anthracyclines and many cytotoxic agents.

Side-effect reporting and safety updates
Patients in the United States can report side effects directly to the FDA through the MedWatch program or by contacting their healthcare provider, who can report on their behalf. Up-to-date safety information, including boxed warnings and new safety communications, is available from the prescribing information and from regulatory and professional oncology organizations.

Drug and supplement interactions
Other anthracyclines or cardiotoxic drugs (such as trastuzumab and some targeted therapies) can increase the risk of heart damage when used with doxorubicin or close in time. Strong inhibitors or inducers of liver enzymes and transporters may affect doxorubicin levels, and certain chemotherapy drugs (for example, cyclophosphamide, paclitaxel, and others) are often combined but require coordinated dosing and monitoring. Some over-the-counter medicines and herbal supplements (such as St. John’s wort or high-dose antioxidants) may interfere with chemotherapy metabolism or effects, so all nonprescription products should be reviewed with the oncology team.

Food, alcohol, and procedures
No specific foods are absolutely contraindicated, but maintaining good nutrition and avoiding raw or undercooked foods during periods of low white blood cells may be advised to reduce infection risk. Excess alcohol use can increase liver and heart stress and should generally be limited or avoided. Recent or planned radiation therapy to the chest may increase the risk of heart damage; some imaging contrast agents and procedures may require extra kidney and heart monitoring.

Precautions and monitoring
Doxorubicin is generally avoided or used with extreme caution in people with severe heart failure, recent heart attack, uncontrolled arrhythmias, or severe liver disease. Before and during treatment, monitoring typically includes complete blood counts, liver function tests, and heart function tests (such as echocardiograms), along with regular blood pressure and symptom checks. Patients should promptly report shortness of breath, swelling, rapid weight gain, chest pain, palpitations, fever, or signs of infection.

Q: Why am I receiving doxorubicin as part of my chemotherapy regimen?
A: Doxorubicin is a core component of many standard treatment combinations because it is effective at killing rapidly dividing cancer cells in diseases like lymphomas, leukemias, sarcomas, and some solid tumors, and your oncology team has chosen it based on evidence that it improves outcomes for your specific cancer.

Q: How long will I be on doxorubicin, and when will I know if it is working?
A: Most regimens use a set number of cycles (often 4–8) given every 2–3 weeks, and your team will usually check scans, blood tests, or bone marrow after the first few cycles to see whether the cancer is shrinking or controlled.

Q: Will my hair definitely fall out, and will it grow back?
A: Doxorubicin commonly causes significant hair loss, usually starting a few weeks after the first treatment, but hair typically begins to grow back after treatment ends, although color or texture can be different.

Q: How is my heart protected while I am getting doxorubicin?
A: Your team limits the total lifetime dose, checks your heart function before and sometimes during treatment, adjusts or stops the drug if problems appear, and may use protective strategies (such as spacing out doses or using other medicines) when appropriate.

Q: What can I do to reduce side effects from doxorubicin?
A: Taking prescribed anti-nausea medicines, staying well hydrated and nourished, promptly reporting fever or new symptoms, following infection-prevention and oral-care instructions, and keeping all lab and follow-up appointments can help manage side effects and allow your team to adjust treatment if needed.

Storage
For patients at home (for example, if a portable infusion pump is used), doxorubicin solutions should be kept in the original, pharmacy-prepared container, protected from light, and stored exactly as labeled (usually refrigerated) and out of reach of children and pets.

Handling
Wear disposable gloves if instructed when handling infusion tubing, pump, or items contaminated with the drug; avoid contact with skin or eyes and wash thoroughly if contact occurs.

Disposal
Unused drug, used tubing, bags, and contaminated materials should not be thrown in household trash or poured down the sink or toilet; return them to the clinic, infusion center, or a hazardous-drug take-back program for safe disposal, following your oncology team’s instructions.